631 Development of highly efficacious and safe targeted cancer immunotherapy via IL12-based TMEkine™ platform
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2020-11-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| _version_ | 1818435570778505216 |
|---|---|
| author | Dahea Lee Donggeon Kim Soomin Ryu Byoung Chul Lee |
| author_facet | Dahea Lee Donggeon Kim Soomin Ryu Byoung Chul Lee |
| author_sort | Dahea Lee |
| collection | DOAJ |
| first_indexed | 2024-12-14T16:54:59Z |
| format | Article |
| id | doaj.art-b8bdb937f28742a8ba76c9e8ec77c79a |
| institution | Directory Open Access Journal |
| issn | 2051-1426 |
| language | English |
| last_indexed | 2024-12-14T16:54:59Z |
| publishDate | 2020-11-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj.art-b8bdb937f28742a8ba76c9e8ec77c79a2022-12-21T22:54:00ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262020-11-018Suppl 310.1136/jitc-2020-SITC2020.0631631 Development of highly efficacious and safe targeted cancer immunotherapy via IL12-based TMEkine™ platformDahea Lee0Donggeon Kim1Soomin Ryu2Byoung Chul Lee3Kanaph Therapeutics, Seoul, Korea, Republic ofKanaph Therapeutics, Seoul, Korea, Republic ofKanaph Therapeutics, Seoul, Korea, Republic ofKanaph Therapeutics, Seoul, Korea, Republic of |
| spellingShingle | Dahea Lee Donggeon Kim Soomin Ryu Byoung Chul Lee 631 Development of highly efficacious and safe targeted cancer immunotherapy via IL12-based TMEkine™ platform Journal for ImmunoTherapy of Cancer |
| title | 631 Development of highly efficacious and safe targeted cancer immunotherapy via IL12-based TMEkine™ platform |
| title_full | 631 Development of highly efficacious and safe targeted cancer immunotherapy via IL12-based TMEkine™ platform |
| title_fullStr | 631 Development of highly efficacious and safe targeted cancer immunotherapy via IL12-based TMEkine™ platform |
| title_full_unstemmed | 631 Development of highly efficacious and safe targeted cancer immunotherapy via IL12-based TMEkine™ platform |
| title_short | 631 Development of highly efficacious and safe targeted cancer immunotherapy via IL12-based TMEkine™ platform |
| title_sort | 631 development of highly efficacious and safe targeted cancer immunotherapy via il12 based tmekine™ platform |
| work_keys_str_mv | AT dahealee 631developmentofhighlyefficaciousandsafetargetedcancerimmunotherapyviail12basedtmekineplatform AT donggeonkim 631developmentofhighlyefficaciousandsafetargetedcancerimmunotherapyviail12basedtmekineplatform AT soominryu 631developmentofhighlyefficaciousandsafetargetedcancerimmunotherapyviail12basedtmekineplatform AT byoungchullee 631developmentofhighlyefficaciousandsafetargetedcancerimmunotherapyviail12basedtmekineplatform |